Showing 1 - 10 of 1,719
regulation, and not by price differences in line with the hypothesis of "regulatory arbitrage". …
Persistent link: https://www.econbiz.de/10010477153
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10013285854
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...
Persistent link: https://www.econbiz.de/10011509446
We investigate behavioral responses to a staggered disruption in the supply of prescription opioids across U.S. states: the introduction of electronic Prescription Drug Monitoring Programs (PDMPs). Using administrative datasets, we find PDMPs curtail the proliferation of prescription opioids....
Persistent link: https://www.econbiz.de/10013177127
Antibiotic resistance constitutes a major health threat. Predicting bacterial causes of infections is key to reducing antibiotic misuse, a leading driver of antibiotic resistance. We train a machine learning algorithm on administrative and microbiological laboratory data from Denmark to predict...
Persistent link: https://www.econbiz.de/10012022285
departure from Ramsey pricing are stated in terms of price regulation and insurance coverage. The resulting outcome is second … increasing in the second best world. As the optimal means-tested insurance, two alternative criteria for vertical equity are …
Persistent link: https://www.econbiz.de/10012157261
We study determinants of COVID-19 vaccine donations from recipients' perspective, especially considering supply chain and institutional weakness (corruption) aspects. Results, based on data from more than 131 nations, show that strengthened supply chains reduced donations. The impacts of...
Persistent link: https://www.econbiz.de/10014393223
We examine the deep roots of preferences for vaccination against COVID-19, moving beyond proximate factors which can only account for part of the observable heterogeneity in the willingness to get vaccinated. Our model on experience-based learning predicts that exposure to past disruptive crises...
Persistent link: https://www.econbiz.de/10014249923
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875